Axoltis Pharma reported that its Phase 2 SEALS trial of NX210c in ALS missed the primary endpoint, but the company says it saw encouraging secondary and exploratory signals.
Post-hoc analyses showed a slower decline in ALSFRS-R versus placebo at week 6, with the effect persisting at later follow-up points.
The company also highlighted biomarker findings, including a reduction in plasma claudin-5, which it says supports blood-brain barrier restoration.
NX210c appeared generally well tolerated, with no major new safety concerns reported.
Despite the miss on the main goal, Axoltis said the data justify continuing development of the ALS candidate.
Sources:
Axoltis Pharma announces topline Phase 2 results for NX210c ...
Axoltis Pharma announces topline Phase 2 results for NX210c in Amyotrophic Lateral Sclerosis
Axoltis Pharma: €18 Million Closed To Advance Phase 2 ...
Latest Axoltis News & Announcements - Distill Intelligence
InSilicoTrials, Axoltis partner to work on potential ALS therapy
Clinical Trials News - Breaking Updates & Insights Worldwide
Authorization to launch phase II clinical trial for ALS
Drug candidate for ALS patients authorised for Phase II trial - Drug Discovery World (DDW)
Fresh capital flows into neurodegeneration, cancer and vascular ...